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Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias
and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an
inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of
upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical
data for apoptosis inhibitors currently in development for the treatment of AML, ALL,
and MDS.
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INTRODUCTION
One of the well-described hallmarks of cancer is the ability to evade apoptosis. Upstream regulators
and downstream effectors of apoptosis carefully regulate the precise dismantling of a cell in
response to a wide variety of internal and external stimuli. At any point along the pathway
malignancies can exploit these interactions for survival. Research convincingly demonstrates that
acute leukemias and myelodysplastic syndrome (MDS) co-opt these mechanisms for both their
development as well as resistance to traditional chemotherapies. Recently, many new drugs that
work to promote apoptosis have been developed and studied. The B cell lymphoma-2 (Bcl-2)
protein family includes key regulator of apoptosis, including the anti-apoptotic protein BCL-2.
Venetoclax, an oral BCL-2 inhibitor and the prototype for this class of drugs, has shown promising
efficacy in the treatment of several hematologic malignancies. First approved in 2016 for the
treatment of relapsed/refractory CLL, venetoclax has now also been recently FDA approved for
the treatment of acute myeloid leukemia (AML). However, to date, none of these drugs have been
approved in acute lymphoblastic leukemia (ALL) or MDS. This review seeks to explain the role
of the intrinsic pathway of apoptosis and the data for drugs targeting the Bcl-2 superfamily in the
treatment of acute leukemias and MDS.
INTRINSIC APOPTOSIS AND THE BCL-2 SUPERFAMILY
Apoptosis is governed by two intertwined pathways that ultimately lead to cell death. The extrinsic
pathway is activated in response to external signaling proteins, like tumor necrosis factor alpha
(TNF-a) and FAS-L, which generate an intracellular signal through transmembrane receptor
proteins. These signals in turn lead to the activation of caspases that are ultimately responsible
for degradation of essential cellular proteins [see (1, 2) for a review of the extrinsic pathway].
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The intrinsic pathway is tightly regulated by the Bcl-2
superfamily of proteins. Following activation of the intrinsic
pathway, a complex interplay between various members of the
Bcl-2 family of proteins culminates in the release of cytochrome-
C from “stressed” cells’ mitochondria by the creation of pores
in the mitochondrial outer membrane, a process denoted as
mitochondrial outer membrane permeabilization (MOMP). The
supergroup members share BCL-2-like homology domains 1-
4 (BH1-BH4) and can be divided into various classes based
on the impact of the protein on the apoptotic outcome of
the cell: sensitizers, activators, suppressors and effectors. For
a cell in resting state, suppressors of apoptosis (BCL-2, BCL-
XL, MCL1, BCL-W among others) bind to effectors (BAX or
BAK) and activators (BID and BIM) and suppress their activity.
Conversely, as a result of upstream cell damage signaling (see
Figure 1), the production of sensitizers and activators is induced.
Sensitizers bind directly to anti-apoptotic proteins which causes
their disassociation from effector and activator proteins. In
turn, activators bind to effectors, inducing a conformational
change in the effectors that allows for their oligomerization.
This oligomerization event allows for the creation of pores in
mitochondria that generates MOMP and induces the release
of cytochrome-C through the mitochondrial membrane. Extra-
mitochondrial cytochrome-C complexes with Apaf-1 which
subsequently oligomerizes into a heptamer known as the
apoptosome and recruits and activates caspase 9. Activated
caspase 9 plays a central role in cleaving other effector
caspases, and this ultimately leads to the proteolytic dismantling
of the cell (3, 4).
Upstream of the intrinsic pathway, the central tumor
suppressor p53 helps to orchestrate the cellular signals leading to
apoptosis. In p53-competent cells, DNA damage initiates a broad
cascade of responses, including the dissociation of p53 from its
inhibitor MDM2 and its rapid translocation to the mitochondria.
Once there, p53, through complex interactions, is thought to
release pro-apoptotic Bax and Bak from inhibitory proteins like
BCL-2 and BCL-XL, which functionally sequesters them and
pushes the “stressed” cell toward apoptosis. Additionally, p53,
when liberated from MDM2, acts as a transcription factor for
BAX itself as well as for the initiator proteins PUMA and NOXA.
PUMA and NOXA bind to BCL-XL, allowing for the release of
Bax to form its effector oligomers. In certain cells, p53 may also
transcriptionally repress BCL-2 (5). The sum of the effects of p53
activation are pro-apoptotic and, in part through its interactions
with the Bcl-2 superfamily, p53-deficient cells may be rendered
chemotherapy-resistant (3–5).
During normal differentiation of hematopoietic cells, the
relative expression of Bcl-2 family of proteins is temporally
and topographically regulated. For example, in the lymphoid
lineage, BCL-2 expression is critical for the development of
B and T lymphoid progenitors from hematopoietic stem cells
(6). Early T-cells demonstrate high levels of expression of
BCL-2 relative to BCL-XL at the CD4-CD8- double negative
stage, but downregulate BCL-2 in favor of BCL-XL during the
CD4+CD8+ double positive stage (7–11). The expression of
BCL-2 increases as the differentiation of T-cells proceeds into
single positive thymocytes (CD4+CD8- or CD4-CD8+) (7, 8)
and memory T-cells maintain relatively high expression (12). On
antigen binding, co-stimulation of the T-cell receptor with CD28
upregulates BCL-XL (13). Similarly, during B-cell maturation,
high levels of BCL-2 are seen early on (pro-B stage), are markedly
lower in intermediate stages of differentiation, and again are
upregulated in the memory B-cell (14, 15).
BCL-2 was first discovered as a partner of IGH in the
translocation of chromosomes 14:18, which is a hallmark of
follicular lymphoma and plays a central role in oncogenesis.
Seminal studies demonstrated that cell lines that have
upregulated anti-apoptosis protein like BCL-2 or MCL-1
do not themselves become cancerous but allow otherwise lethal
mutations in the cell cycle to be transmitted to daughter cells.
Additionally, upregulation of these inhibitory proteins by various
means in a wide variety of tumor subtypes contributes to their
resistance to chemotherapy (4). Taken together, the central role
of the Bcl-2 superfamily in the development and progression
of cancer, as well as in mediating chemotherapy resistance, has
made it a highly sought-after therapeutic target.
PRE-CLINICAL DEVELOPMENT OF BH3
MIMETICS
The targeting of BCL-2 proteins was initially evaluated using
antisense mRNA compounds. Oblimersen is a BCL-2 antisense
oligonucleotide that is complementary to part of the BCL-2
mRNA coding region, allowing for binding of BCL-2 mRNA
to inhibit BCL-2 protein translation. Preclinical studies utilizing
CD34+marrow cells, BCL-2-positivemyeloid cell lines andAML
cells demonstrated inhibition of BCL-2 expression, decreased cell
survival, and decreased clonal proliferation in cultures treated
with BCL-2 antisense, as well as synergistic killing of AML cells
in the presence of chemotherapeutics (16).
The development of BH3 mimetics allowed for effective
targeting of anti-apoptotic proteins in tumors that are dependent
on BCL-2 or BCL-XL and opened up a new avenue for
targeted therapeutics in hematologic malignancies. These
molecules inhibit the Bcl-2 family of anti-apoptotic proteins
by occupying their BH3 binding groove. These include the
synthetic small molecule BH3mimetics developed by researchers
at Abbvie, which were discovered utilizing nuclear magnetic
resonance (NMR) to identify fragments with BCL-XL binding
properties (17).
GX15-070/obatoclax was amongst the first compounds
described to modulate the activity of the pro-survival Bcl-2
family members via inhibition of BH3 peptide binding. It is a
polypyrrole developed from a natural compounds screen, which
functions as a non-selective pan-BCL-2 inhibitor, binding BCL-
2, BCL-XL, BCL-W, MCL1, among others. In vitro studies of
obatoclax demonstrated antileukemic activity against AML cell
lines and primary AML samples, via apoptosis and decreased
proliferation (18). Mechanistically, its pro-apoptotic activity was
demonstrated to involve release of Bim and Bak from BCL-2 and
MCL1 with the formation of an active Bak/Bax complex. GX15-
070/obatoclax has also been shown to overcome MCL1 mediated
resistance to apoptosis (19).
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FIGURE 1 | Intrinsic pathway. In the resting state, suppressors BCL-2, MCL1, BCL-XL, and BCL-W bind to and inhibit effectors and activators, thus preventing
downhill cascade leading to apoptosis. The site of inhibition of key BCL-2 family inhibitors is noted by brackets. In response to stress, sensitizers bind to the
suppressors, releasing the inhibitory effect of suppressors on effectors and activators. Thus, conformational change and oligmerization ensues with subsequent
MOMP formation and release of cycotochrome C. Cytochrome C and Apaf-1 oligmerize into the apoptosome, leading to activation of caspases and, finally, cell death.
ABT-737 was the first of the synthetic small molecule
BH3 mimetics that was demonstrated to exhibit high potency
inhibition of BCL-2, BCL-XL, and BCL-W, with greater affinity
binding of these proteins by two to three orders of magnitude,
compared to prior compounds (20). Notably, this molecule has
been very useful in demonstrating the anti-tumor effect of BH3
mimetics in preclinical studies; however, solubility issues have
prevented its use in the clinical setting. Specifically, regarding
its activity in acute leukemias, ABT-737 was shown to induce
apoptosis of AML cell lines, primary AML blast cells and
stem cells, and in a murine xenograft model in vivo (21). In
this study, overexpression of MCL-1 was shown to diminish
the activity of GX15-070/obatoclax, highlighting a resistance
mechanism to BCL-2/BCL-XL inhibition induced apoptosis.
Further work demonstrated that ABT-737 induces the activation
of extracellular receptor activated kinases (MAPK/ERK Kinases),
resulting in upregulation of MCL-1 in AML cells (22). In this
study, use of MEK inhibitors abrogated this effect of ABT-737,
and combination treatment with ABT-737 and a MEK inhibitor
resulted in potent synergistic killing of AML cell lines, primary
AML blasts, and murine xenografts (22). ABT-737 additionally
has been shown to have a potent synergistic effect in inducing
killing of primary AML andMDS cells when used in combination
with the hypomethylating agent azacitidine (23, 24). Treatment
of primary AML cells with azacitidine has been shown to
reduce MCL-1 expression, which likely accounts for this synergy
(25). Of note, combination treatment with a FLT3 inhibitor
in AML primary cells with an activating FLT3 mutation also
demonstrated a synergistic effect (26). ABT-737 has further been
shown to have activity in pediatric ALL, synergistically enhancing
the effect of vincristine, dexamethasone, L-asparaginase in ALL
cell lines and mice bearing ALL xenografts (27).
ABT-263/navitoclax, was subsequently developed via
modification of ABT-737 at 3 molecular positions, resulting
in oral bioavailability allowing for therapeutic use, while
maintaining high potency inhibition of BCL-2, BCL-XL,
and BCL-W (28, 29). In preclinical studies, navitoclax was
demonstrated to have significant activity in vitro against ALL cell
lines, as well as in ALL xenograft models (30). However, it was
noted to have lower activity against CLL cells compared to its
predecessor ABT-737, likely due to increased albumin binding
(31). Additionally, its clinical use was limited by dose-dependent
thrombocytopenia (32–34), due to on-target inhibition of
BCL-XL, with resulting platelet apoptosis as well as impaired
hemostatic functions of residual platelets (35, 36).
ABT-199/venetoclax is a modified BH3-mimetic which was
subsequently designed to be highly selective for BCL-2 but not
bind BCL-XL, as opposed to its predecessors. This specificity
of venetoclax has been shown both in vitro and in vivo to
result in a highly potent anti-tumor effect in BCL-2 dependent
malignancies, while also sparing platelets. This specificity makes
it a particularly attractive therapeutic candidate for acute
leukemias, where thrombocytopenia is generally a significant
complication of the disease, even prior to treatment. Pre-
clinical studies have shown significant anti-tumor activity of
venetoclax in acute leukemias. Using AML cell lines, murine
AML xenografts, and primary patient AML myeloblasts Pan
et al. demonstrated rapid venetoclax-induced apoptosis of AML
cells both in vitro and in vivo (37). This study also described
a novel method of determining a cell’s relative dependence on
anti-apoptotic proteins for survival, called BH3 profiling. In this
method, exogenous sensitizers and activators are added to a
cell and the degree of MOMP is determined. Using the unique
binding patterns of the sensitizing and activating BH3 proteins,
Frontiers in Oncology | www.frontiersin.org 3 March 2019 | Volume 9 | Article 192
McBride et al. BCL-2 Inhibition in Acute Leukemias and MDS
the group determined which anti-apoptotic proteins a cell was
reliant on for continued survival. For instance, mitochondria that
depolarize in the presence of exogenous HKR, which is known
to exclusively bind and repress BCL-XL activity, would be said
to be BCL-XL dependent. Using this technique, the group found
a tight correlation between samples that were BCL-2 dependent
and their sensitivity to ABT-199, suggesting on-target activity and
indicating a potential biomarker for further exploration.
While the inhibition of BCL-2 by venetoclax results in
significant anti-leukemic activity, overexpression of MCL-1
can lead to venetoclax resistance and has MCL-1 protein
overexpression has been shown in venetoclax-resistant cells.
Therefore, there is strong interest in combination therapy with
drugs that overcome this mechanism of resistance. ABT-199
treatment of AML cells increases levels of MCL-1 protein, with
resultant MCL-1 sequestration of the pro-apoptotic protein Bim,
preventing the induction of apoptosis (38). Co-treatment of
AML cells with venetoclax and either daunorubicin or cytarabine
overcomes this resistance by increasing DNA damage, which
in turn prevents MCL-1 upregulation (38). As with ABT-737,
venetoclax in combination with azacitidine results in a synergistic
anti-leukemic effect via azacitidine suppression of MCL-1. The
venetoclax/azacitidine combination showed less potency against
AML cell lines in vitro compared to ABT-737, but similar potency
against primary AML and MDS samples tested ex vivo (23, 24).
Combined treatment with venetoclax and the selective MCL-1
inhibitor A-1210477 abrogates MCL-1 sequestration of Bim and
results in synergistically induced apoptosis in AML cell lines and
primary patient samples (39). Bypassing the MCL-1 resistance
mechanism has also been investigated with the pan-histone
deacetylase inhibitor panobinostat, which was demonstrated to
upregulate Bim, resulting in sustained Bim levels in the presence
of venetoclax and a synergistic anti-leukemia effect in AML cell
lines and patient samples (40).
The combinations of venetoclax and a variety of newer
cancer therapeutics have additionally been investigated in
preclinical studies in AML with promising results. Venetoclax
and the cyclin-dependent kinase (CDK) inhibitor alvocidib
were found to act synergistically in venetoclax sensitive and
resistant AML models, with alvocidib acting to decrease MCL-
1 and increase pro-apoptotic proteins Bim and NOXA, thereby
complementing the venetoclax mechanism of action (41).
Pevonedistat (MLN4924), an inhibitor of the Nedd8 activating
enzyme, has also been shown to synergize with venetoclax
in AML cell lines and in fresh AML patients’ cells, through
neutralization of MCL-1 and activation of the pro-apoptotic
proteins Bax and Bak (42). Cotreatment of primary AML blasts
and AML cell line xenografts with venetoclax and the PI3
kinase/mTOR inhibitor GDC-0980 also resulted in enhanced
apoptosis, involving MCL-1 downregulation and Bax activation,
suggesting that coadministration of PI3K and BCL-2 inhibitors
may be effective in AML treatment (43).
The anti-leukemic effect of venetoclax in combination with
the MDM2 antagonist idasanutlin has also recently been
investigated. MDM2 is a negative regulator of the p53 tumor
suppressor, and disruption of MDM2-p53 binding by idasanutlin
allows for p53 activation and restores p53-dependent cell cycle
arrest and apoptosis (44). Therefore, it was hypothesized that
concomitant inhibition of BCL-2 and MDM2 would allow for
an enhanced anti-leukemic effect by restoring key apoptotic
and tumor suppressor pathways simultaneously. Indeed, the
combination of venetoclax and idasanutlin results in enhanced
anti-tumor activity compared to either treatment alone in p53
wild type AML cell lines in vitro and AML xenograft models
in vivo (45). Further, combining these therapeutics was shown
to overcome resistance to either drug alone, with p53 activation
promotingMCL-1 degradation and BCL-2 inhibition shifting the
p53 activation response from G1 cell cycle arrest to apoptosis,
resulting in prolonged survival in murine xenograft models of
resistant AML (46).
Overall, these studies suggest that the therapeutic effect of
venetoclax in AML can be optimized in combination with other
therapies, particularly those targeting leukemic cell mechanisms
of venetoclax resistance. Interestingly, isocitrate dehydrogenase
(IDH) 1 and 2 mutation status may also affect the response to
BCL-2 inhibition, as IDH1 and IDH2 mutant primary human
AML cells have been demonstrated to be more sensitive to
venetoclax treatment than those with wild type IDH 1/2 (47). In
this study, the mechanism of increased sensitivity to venetoclax
was demonstrated to be via production of the oncometabolite
R-2-hydroxyglutarate (R-2HG) by mutant IDH 1/2, with R-
2HG mediated inhibition of cytochrome c oxidase activity
in the mitochondrial electron transport chain, resulting in a
lower mitochondrial threshold to trigger apoptosis under BCL-
2 inhibition.
When considering the potential use of BH3 mimetics in
MDS, blockade of BCL-2 with either venetoclax or ABT-
737 has been demonstrated to result in significant toxicity to
primary bone marrow cells from patients with high risk MDS
or secondary AML, as demonstrated by reduction in CD34+
cells and decreased colony-forming capacity in vitro, but has no
effect on bone marrow cells from patients with low risk MDS
or healthy controls (48). This suggests that venetoclax treatment
can overcome apoptotic resistance of high risk MDS cells and
possibly delay disease progression in this patient population.
Regarding the potential of venetoclax use in ALL treatment,
it has also been shown to have activity against T-cell ALLs in
preclinical studies utilizing childhood ALL xenografts. Notably,
the sensitivity of T cell ALLs to venetoclax appears to be
dependent on the subtype of ALL and more specifically on
the maturation stage of the leukemia cells (49, 50). Early T-
cell precursors highly express BCL-2 and, correspondingly, ALL
with an early T-cell progenitor phenotype show sensitivity
to venetoclax. However, more mature subgroups of ALL are
dependent on BCL-XL and not BCL-2, and, consequently,
show sensitivity to navitoclax but not to venetoclax (49). An
exception is mixed lineage leukemia (MLL) rearranged ALL,
where venetoclax has been shown to recapitulate the activity of
navitoclax (51).
Since MCL-1 overexpression allows for resistance to the
BCL-2 inhibitors, the development of compounds that directly
target MCL-1 is also of significant interest. Developing such
compounds has proved challenging due to the shallower,
less flexible binding site of MCL-1; however, direct MCL-1
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inhibitors have recently been described (52). Amongst these is
marinopyrrole A/maritoclax, a natural product identified from
marine streptomycetes which bindsMCL-1, but not BCL-XL, and
disrupts the MCL-1-Bim interaction and induces proteosomal
degradation of MCL-1 (53). In vitro studies have shown that
maritoclax has an additional MCL-1-independent pro-apoptotic
mechanism involving accumulation of mitochondrial reactive
oxygen species (54). Maritoclax was demonstrated to induce
apoptosis of AML cell lines and primary AML cells with elevated
MCL-1 levels via MCL-1 downregulation and synergized with
ABT-737 to overcomeMCL-1-mediated ABT-737 resistance (55).
As with the small molecule BH3 mimetics, NMR-based
fragment screen was used to identify compounds that inhibit
MCL-1, including S63845 (and its derivative S64315) and
A1201477. Intriguingly, these compounds cause increased MCL-
1 protein levels, but also effectively disrupt the MCL-1-Bim
interaction to induce apoptosis. S63845 was demonstrated to
induce potent killing ofMCL-1-dependent cancer cells, including
leukemia and lymphoma cells, by activation of the BAX/BAK-
dependent apoptotic pathway (56). A1201477 additionally was
shown to induce synergistic effects with navitoclax in a variety
of cancer cell lines (57).
CLINICAL DEVELOPMENT
Oblimersen, BCL-2 Antisense
Anti-sense BCL-2, oblimersen sodium, was investigated early
on in the development of therapy targeting this anti-apoptotic
family. It was administered as a continuous infusion and
showed clinical activity in patients with FLAG chemotherapy
(fludarabine, cytarabine, and granulocyte stimulating factor) with
relapsed or refractory AML or ALL (58) and with cytarabine
and daunorubicin in untreated AML (59). Moore et al. further
demonstrated clinical activity with 25% of patients achieving a
response (60). Further, studies were halted, as oblimersen was
limited by its continuous infusion administration and the lack of
follow-up trials demonstrating clinical effectiveness.
Obatoclax, Pan-BCL-2 Antagonist
Schimmer et al. investigated obatoclax, the pan-BCL-2
antagonist, in patients with AML, MDS, CLL, and ALL
(61). Patients in this study were either ineligible for induction
chemotherapy or had relapsed disease. Obatoclax was well
tolerated in the study population. The most common adverse
events (AE) were CNS-related, including somnolence, dizziness,
fatigue, euphoric mood, and gait disturbance immediately
following infusion; these resolved within a few hours after
infusion administration. Complete remission was seen in one
of 25 patients with AML, and three of 14 patients with MDS
showed improvement of transfusion dependence. Arellano
et al. investigated obatoclax use in patients with untreated
myelodysplastic syndromes with anemia or thrombocytopenia
(62). Dosing of 60mg every 2 weeks seemed tolerable, with AE
of euphoric mood, nausea, vomiting, grade 3-4 AE of anemia,
thrombocytopenia, and pneumonia. This study was terminated
as the response rate of 8% was below the pre-determined
threshold for continuation.
BCL-2 Inhibitors
Clinical Trials in AML
The initial clinical trials of the BCL-2 inhibitor venetoclax in
AML were focused on dose finding, in light of the uncertain
risk/benefit profile associated with tumor lysis syndrome (TLS),
as well as on obtaining a preliminary assessment of the clinical
efficacy of the drug. In a phase II study, Konopleva et al. evaluated
venetoclax monotherapy at a dose of 800mg in individuals
with relapsed/refractory AML, or those unfit for intensive
chemotherapy (63). In this study venetoclax had a favorable
side effect profile as well as measurable clinical activity, with a
19% overall response rate (ORR). Common adverse events were
nausea, vomiting, diarrhea, as well as febrile neutropenia and
hypokalemia. Importantly, no TLS was observed in significant
contrast to CLL where life-threating TLS has been seen.
In consideration of treatment of older patients with AML,
Lin et al. designed a phase I study investigating venetoclax use
with low-dose cytarabine in treatment-naïve patients aged >65
years with AML (64). Preliminary results of the study found an
acceptable safety profile, with febrile neutropenia as the most
prevalent adverse event. Tumor lysis syndrome (TLS) was not
observed. Venetoclax dosing of 600 and 800mg were assessed in
the phase 1 portion of the study, with findings supporting 600mg
dosing moving forward in phase 2. Preliminary study findings
showed promising clinical activity in this patient population,
with an overall response rate of 44% in the phase I cohort. This
clinical trial is ongoing with expected completion date of May
2019 (NCT02287233).
A further phase I study in newly diagnosed AML patients
older than 65 years has been conducted by DiNardo et al.,
evaluating the efficacy of venetoclax in combination with
the hypomethylating agents azacitidine or decitabine (65).
Venetoclax doses of 400, 800, and 1,200mg were assessed in this
study, with doses of 400 and 800mg utilized in the expansion,
and patients were divided into subgroups based on the venetoclax
dose and the hypomethylating agent received. Findings from
this study have recently been published with impressive results
and have led to accelerated FDA approval of venetoclax in
this clinical setting. Study results include data analysis of 145
patients with a median age of 74 years and a median time on
study of 8.9 months (66). Poor-risk cytogenetics were present in
49% of the study population. In the intent-to-treat population
(including all doses of venetoclax), the rates of complete response
(CR) and complete response with incomplete count recovery
(CRi) were 37 and 30%, respectively, with an ORR (CR +
CRi + partial response) of 68%. Evaluation of defined cohorts
demonstrated CR + CRi rates of 73% for those who received
400mg venetoclax and 65% for those who received 800mg
venetoclax. Of those patients who received 400mg venetoclax +
a hypomethylating agent, the response rates were similar between
azacytidine and decitabine cohorts (76 and 71%, respectively).
The median duration of CR + CRi was 11.3 months for all
patients and 12.5 months for the 400mg venetoclax group.
The median overall survival was 17.5 months for all patients
and had not been reached for the 400mg venetoclax cohort.
Further, the authors evaluated minimal residual disease (MRD)
status and found that amongst those who achieved CR/CRi,
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29% (28/97) had at least 1 assessment of MRD <10−3, and of
those with MRD negativity, the median duration of response
and overall survival were not reached. The most common
toxicities were gastrointestinal and hematologic in nature, noting
that many hematologic adverse events were attributable to the
underlying hematologic disease, and the most common grade 3
and 4 adverse events included febrile neutropenia, cytopenias,
and pneumonia. Notably, subgroup analyses also demonstrated
meaningful responses in patients with poor risk cytogenetics. In
particular, those with NPM1 mutations had a quite favorable
outcome with venetoclax-based therapy, with CR + CRi rate
of 91.5% and median overall survival and duration of CR
+ CRi not reached. NPM1 mutation status was additionally
found to be a statistically significant predictor of favorable
outcome. Patients harboring FLT3 and IDH1/2 mutations also
demonstrated impressive responses, with CR + CRi rates of 72
and 71%, respectively.
Looking ahead, results of a phase 3 randomized, double-blind,
placebo-controlled study investigating venetoclax use in older
AML patients are anticipated to be favorable (67). The study is
designed to evaluate the effect of venetoclax (at 400mg dose) in
combination with azacitidine on overall survival and remission
rates as compared to the combination of azacitidine with placebo.
Secondary outcomes include event free survival and quality life
measures. The study opened in February 2017, with a target
enrollment of 400 patients and an estimated completion date of
the trial is January 2021 (NCT02993523), though given the FDA
approval of this medication, continued accrual may be slow.
The use of venetoclax in combination with other agents
for the treatment of AML is also being investigated. DiNardo
and colleagues recently reported findings of various venetoclax
combinations in relapsed and refractory AML, MDS, and
blastic plasmacytoid dendritic cell neoplasm (BPDCN) (68).
A total of 43 patients with median age 68 years (range
25–83) were evaluated, the majority of whom had already
received more than 2 s line regimens. The combination regimens
included decitabine, azacitidine, low-dose cytarabine, fludarabine
plus cytarabine, and cladribine plus cytarabine. Midostaurin,
sorafenib, and ruxolitinib were also used in the few patients
who had -FLT3-ITD or JAK2-mutations. Twenty-one percent
of patients had complete response, complete remission with
incomplete blood count recovery, or morphologic leukemia-
free state. Interestingly, they also found a 27% response rate
amongst patients with IDH-1 or IDH-2 mutations (11 patients
total) when an IDH inhibitor was used in combination with
venetoclax, despite previous non-responsiveness to an IDH-1
or IDH-2 inhibitor. The authors concluded that low intensity
chemotherapy in combination with venetoclax is an option
for therapy in multiply relapsed/refractory AML, MDS, and
BPDCN. DiNardo et al. are also currently investigating the
safety and tolerability of venetoclax when utilized in induction,
consolidation, and maintenance of newly diagnosed or refractory
AML together with standard intensive care chemotherapy with
fludarabine, cytarabine, idarubicin, filgrastim (FLAG-IDA). The
study is actively recruiting, and its completion date is estimated
for September 2024 (NCT03214562). Additionally, this group of
researchers will be investigating the safety and tolerability as well
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as clinical efficacy of venetoclax used with ivosidenib (AG120) in
IDH-1 relapsed or refractory AML. The study opened in March
2018 and is actively enrolling with an estimated completion date
of September 2020 (NCT03471260).
Clinical Trials in ALL
An ongoing phase I, open-label, multicenter trial is investigating
venetoclax and navitoclax use with standard chemotherapy
regimen in young adults and pediatric patients with T-cell
and B-cell ALL (69). Serious adverse events observed in this
trial are comparable to other studies, and include nausea,
vomiting, abdominal pain, somnolence, and pseudomonas sepsis.
Preliminary data reveal all four of the enrolled patients achieved a
clinical response, either complete remission, complete remission
with incomplete platelet recovery, or complete remission
with incomplete marrow recovery. One patient had disease
progression at 3.4 months and discontinued trial therapy.
Estimated completion date of trial is June, 2020 (NCT03181126).
This study, in conjunction with NCT03236857, which is
investigating venetoclaxmonotherapy followed by chemotherapy
regimens (70), will help further elucidate the clinical utility of
targeting this anti-apoptotic family in pediatric and adult ALL.
Palmisiano and colleagues initiated an ECOG-ACRIN,
multicenter phase Ib/II study (EA9152) investigating the
combination of venetoclax and liposomal vincristine in
relapsed/refractory or unresponsive to treatment childhood
and adult B-cell and T-cell ALL (NCT03504644). This study
will seek to elucidate the optimal dose of venetoclax in this
combination regimen in patients with relapsed/refractory T/B-
ALL by establishing the maximum tolerated dose (MTD), as well
as assessing the preliminary efficacy of the combination, using
response rate as a primary endpoint. This trial started April,
2018 and is currently enrolling, with expected completion date
April, 2021.
Clinical Trials in MDS
Data demonstrating efficacy of BCL-2 inhibition in MDS is
largely preclinical at this point. As noted above, DiNardo
et al. did include patients with MDS in addition to those
with AML in their recent report of 43 patients treated with
venetoclax combination therapy for relapsed/refractory disease
(68). However, amongst those 43 patients, only 2 carried a
diagnosis of MDS and only 1 one of these patients responded.
The patient who responded notably had MDS with complex
cytogenetics and mutations of RUNX1 and TP53, and had
been extensively pretreated, including prior azacitidine and
decitabine as well as two prior allogeneic haplo-identical stem cell
transplants. However, despite the paucity of clinical data of BCL-
2 inhibitors in MDS, there are current clinical trials evaluating
venetoclax in MDS which are actively recruiting. The two trials
specifically limited to those with patients with MDS are phase
1b studies sponsored by AbbVie. These include evaluation of
venetoclax in combination with azacitidine in treatment-naïve
higher-risk MDS patients (NCT02942290) and evaluation of
venetoclax alone or with azacitidine in relapsed/refractory MDS
patients (NCT02966782). Both studies opened in early 2017,
with estimated primary completion dates of September 2019 and
August 2020, respectively.
MCL-1 INHIBITORS
Currently, there are trials involving MCL-1 inhibitor use in
AML/MDS ongoing as well, with initial aims investigating
tolerated doses and adverse effects of these intravenous agents.
The first in human trial of the MCL-1 inhibitor AMG176
(Amgen) in patients with relapsed/refractory multiple myeloma
and AML is currently active (NCT02675452). The trial start date
was June 2016 with an expected primary completion date of May,
2020. The primary objective of this phase I trial is to investigate
the safety profile and maximum tolerated dose of AMG176 in
patients with relapsed/refractory AML and multiple myeloma,
with a secondary objective to evaluate preliminary efficacy of
the therapeutic agent. A second study investigating another
MCL-1 inhibitor, S64315 (Institut de Recherches Internationales
Servier) in patients with AML or MDS is also currently active
(NCT02979366). This phase 1 open-label, non-randomized, non-
comparative study will investigate the safety, tolerability, and
incidence of dose-limiting toxicities of the drug. The study started
March 2017 with estimated date of completion of October 2020.
CONCLUSIONS
The ability of cancers to upregulate the Bcl-2 family of anti-
apoptotic proteins as a means to evade apoptosis represents a
key mechanism for treatment resistance and relapse in acute
leukemia and MDS. Targeted inhibition of the anti-apoptotic
Bcl-2 proteins has been shown to have impressive efficacy in
the treatment of several hematologic malignancies, with current
FDA approvals of venetoclax for the treatment of CLL and AML.
Preclinical studies have demonstrated substantial anti-leukemic
activity of the BH3mimetics, and there aremany ongoing trials to
confirm these findings. Given its bioavailability and tolerability,
venetoclax is the main BH3 mimetic in these current clinical
investigations (see Table 1). While these studies are ongoing,
many questions remain. The anti-leukemic activity of the BH3
mimetics is limited by drug resistance mechanisms that are
gradually being characterized in pre-clinical models, in vitro and
in vivo, and while the primary mechanisms of resistance in vivo
remain unclear, clinical studies thus suggest that combination
strategies are able to overcome resistance and lead to clinical
responses. Determining which combination therapies provide
optimal clinical efficacy is a very important goal, moving forward,
and further studies are needed to explore novel combination
strategies. The role of venetoclax and other BH3 mimetics in
standard induction and consolidation therapy is also of great
interest. Further, determining which subgroups of patients are
likely to derive the most clinical benefit from BH3 mimetics
would be quite impactful clinically, and the use of BH3 profiling
and the identification of other potential biomarkers in leukemia
and MDS patients to guide the therapeutic application of these
drugs requires further investigation. Despite these uncertainties,
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inhibition potentially, represent a significant advance in targeted
treatment approaches to hematologic malignancies and are very
promising in acute leukemia and MDS treatment.
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